NCT06879262View on ClinicalTrials.gov

Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 15, 2025

Primary Completion Date

October 1, 2027

Study Completion Date

October 31, 2027

Conditions
R/R NHL
Interventions
BIOLOGICAL

CAR1922T2 T cells（Targeting CD19 and CD22 with CAR-T cells）

Administer a single infusion of CAR1922T2 T cells to this group of patients following fludarabine plus cyclophosphamide (F+C) lymphodepletion

All Listed Sponsors
lead

Tongji Hospital

OTHER